Sentence examples for changes in prostate from inspiring English sources

Little is known about the histological changes in prostate biopsies caused by the prostatic-specific antigen (PSA -based vaccine.

Future studies must be able to link changes in systemic metabolism to local metabolic changes in prostate, which mandates a deeper understanding of the fundamental metabolic infrastructure regulating prostatic differentiation and what allostatic changes may occur in response to systemic metabolic stress.

The answer may be found in genetic changes in prostate cancer cells that signal a higher threat.

Such calculations and values address vital strength- and weight-of-the-evidence questions: (1) how sensitive were the various studies to detect changes in prostate weight, particularly the negative replicate studies and (2) what were the p values; were negative studies robust or only marginal in their inability to find an effect?

This study was designed to validate a fully automated adaptive planning (AAP) method which integrates automated recontouring and automated replanning to account for interfractional anatomical changes in prostate cancer patients receiving adaptive intensity modulated radiation therapy (IMRT) based on daily repeated computed tomography (CT -on-rails images.

Preliminary calculations indicated that the two subsequent replicating studies were indeed more sensitive to changes in prostate weight in comparison to the original study, having reasonable power to detect an effect at only 50% of the response reported in the original study.

It has been suggested that changes in prostate-specific antigen (PSA) over time (ie, PSA velocity [PSAV]) aid prostate cancer detection.

For model validation in the absence of any other pertinent marker, we used the clinically measured changes in prostate-specific antigen (PSA) levels as a correlate of tumor burden.

Point and 95% CI estimates will be calculated for the changes in prostate-specific symptoms, quality of life, psychological well-being, self-confidence in managing own health, and ongoing medical and support needs between the two groups.

This will provide a satisfactory number of participants for estimating the variation within the sample (ie, the SD of the outcome measures), in order to inform the power calculation for a future phase III trial, which would be powered to detect clinically relevant changes in prostate-related health and cost-effectiveness.

Loss of heterozygosity (LOH) is the most consistent genetic change in prostate cancer (CaP).